华熙生物斥资1.38亿港元，拿下圣诺医药9.44%股权

Group 1 - Sanofi Pharmaceutical announced a subscription agreement with four investors, including Huaxi Biotechnology (Hong Kong) Co., Ltd., to issue 17.3524 million new shares at HKD 12 per share, raising approximately HKD 208.2 million, which accounts for 14.16% of the enlarged share capital [1] - Following the announcement, Sanofi Pharmaceutical's stock price surged nearly 23% on the day of the announcement and continued to rise by nearly 7% the next day, reaching HKD 19.65 per share [2] - Huaxi Biotechnology's strategic investment in Sanofi Pharmaceutical is driven by optimism regarding the development prospects of small nucleic acid drugs and RNAi technology, which have expanded applications in metabolic diseases, tumors, and medical aesthetics [2] Group 2 - Sanofi Pharmaceutical focuses on new drug development centered around RNA interference technology, possessing proprietary delivery platforms such as GalNAc and PNP, with the PNP platform being the first in Asia to achieve targeted delivery of small nucleic acids to non-liver tissues [3] - The core RNAi therapy product STP705 has completed Phase I clinical research for targeted fat reduction in the U.S. and is the first drug to achieve 100% complete clearance in Phase II trials for skin basal cell carcinoma patients [3] - Despite these advancements, Sanofi Pharmaceutical has not yet achieved profitability, reporting a loss of HKD 3.698 million in the first half of 2025 and an expected annual loss of HKD 51.38 million for 2024 [3] Group 3 - Huaxi Biotechnology is undergoing a transformation due to industry conditions and cyclical factors, with its main revenue source, skin science innovation, declining significantly [4] - The company's revenue dropped from HKD 6.359 billion in 2022 to HKD 5.371 billion in 2024, and net profit fell from HKD 971 million to HKD 174 million [4] - In the first half of this year, Huaxi Biotechnology's revenue decreased by 19.57% year-on-year to HKD 2.261 billion, with income from skin science innovation down by 33.97% to HKD 912 million [4]